TNFSF11 and ovarian cancer: Studies in ovarian cancer patients have consistently shown increased RANKL expression, a high RANKL/OPG ratio, and elevated circulating CTX, a marker of bone resorption, reflecting the accelerated bone turnover typical of these patients [46].